1. Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study
- Author
-
J. Barrat, Gillet Jy, M.A. Domin, Philippe E, G. Magnin, M.A. Bruhat, André G, R. Erny, Faguer B, J.M. Kuhn, J.J. Leng, P. Lopes, M. Buvat-Herbaut, B. Hedon, and E. Drapier-Faure
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Administration, Oral ,Endometrium ,Bedtime ,General Biochemistry, Genetics and Molecular Biology ,Oral administration ,medicine ,Humans ,Amenorrhea ,Progesterone ,Aged ,Gynecology ,Estradiol ,medicine.diagnostic_test ,business.industry ,Estrogen Replacement Therapy ,Obstetrics and Gynecology ,Hormone replacement therapy (menopause) ,Middle Aged ,Hyperplasia ,medicine.disease ,Menopause ,medicine.anatomical_structure ,Patient Compliance ,Female ,medicine.symptom ,business ,Endometrial biopsy - Abstract
The effects of oral micronized progesterone on the endometrium and bleeding pattern have been assessed in a multicenter study of 101 postmenopausal patients. During a minimum of 6 cycles, the participants received either percutaneous 17 beta-estradiol (1.5 mg/day) associated with micronized progesterone (100 mg/day), given at bedtime for 21/28 days or 25 days/calendar month (n = 98) [1], or E2 (3 mg/day) for 25 days associated with progesterone (300 mg/day), from day 16 to day 25 (n = 3) [2], according to their willingness to induce, or not, cyclic withdrawal bleeding. Each endometrial biopsy performed at 6-month minimum was assessed by two independent pathologists: results showed 61% quiescent without mitosis, 23% mildly active with very rare mitoses and 8% partial secretory endometrium. The remaining biopsies showed inadequate tissue (4%) or a sub-atrophy (4%). No hyperplasia was found by any pathologist. In the case of inadequate material, the mean thickness of endometrial mucosa measured by ultrasonography was 3.9 mm. Amenorrhea incidence was 93.3 and 91.6% at the 3rd and 6th month of therapy, respectively. No bleeding occurred in more than 80% of women. The results show that a low dose of oral progesterone (100 mg/day), given during 25 days, efficiently protects the endometrium by fully inhibiting mitoses and induces amenorrhea in the majority of postmenopausal women, allowing better compliance to long-term therapy.
- Published
- 1994